Skip to main content
Shenzhen Salubris Pharmaceuticals Co., Ltd. logo

Shenzhen Salubris Pharmaceuticals Co., Ltd. — Investor Relations & Filings

Ticker · 002294 ISIN · CNE100000FW8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,658 across all filing types
Latest filing 2021-10-25 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002294

About Shenzhen Salubris Pharmaceuticals Co., Ltd.

https://www.salubris.com

Shenzhen Salubris Pharmaceuticals Co., Ltd. is a research-driven enterprise focused on the development, manufacturing, and commercialization of innovative drugs and medical devices. The company specializes in therapeutic areas including cardiovascular diseases, chronic kidney disease, and metabolic disorders. Its product portfolio features proprietary treatments such as Allisartan Isoproxil for hypertension and Clopidogrel Bisulfate for anti-platelet therapy. Salubris maintains an integrated value chain encompassing research and development, active pharmaceutical ingredient production, and finished dosage manufacturing. The firm emphasizes innovation through its dedicated R&D centers and strategic focus on biologics and small molecule drugs, aiming to provide comprehensive clinical solutions for chronic conditions.

Recent filings

Filing Released Lang Actions
独立董事关于公司有关事项所发表的独立意见
Regulatory Filings Classification · 95% confidence The document is a statement of independent directors expressing their independent opinion on the company's asset impairment provision. It references compliance with company law, stock exchange listing rules, and accounting standards. The document is short (550 characters) and contains an opinion rather than detailed financial data or a full audit report. It is not a full Annual Report, Audit Report, or financial statement. It is a formal opinion related to governance and compliance matters, which fits best under Regulatory Filings (RNS) as it does not fit other specific categories and is a regulatory compliance-related statement.
2021-10-25 Chinese
2021年第三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "深圳信立泰药业股份有限公司 2021 年第三季度报告" which translates to "Shenzhen Salubris Pharmaceuticals Co., Ltd. 2021 Third Quarter Report." It contains detailed financial data including balance sheets, profit and loss statements, shareholder information, and notes on financial performance for the third quarter of 2021. The presence of comprehensive financial statements and analysis for a period shorter than a full fiscal year indicates this is an Interim / Quarterly Report. The document length is substantial (15,000 characters), and it contains actual financial data rather than just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q3 2021
2021-10-25 Chinese
第五届董事会第二十一次会议决议公告
Regulatory Filings Classification · 95% confidence The document is an announcement of the resolutions passed at the 21st meeting of the 5th Board of Directors of Shenzhen Salubris Pharmaceuticals Co., Ltd. It includes approval of the company's 2021 Q3 report and an asset impairment provision. The document is short (1073 characters) and primarily serves as a formal announcement of board decisions rather than containing the full quarterly report or detailed financial statements. It references the 2021 Q3 report being available on other platforms, indicating this is not the report itself but an announcement of board resolutions. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and board meeting resolution notice, not as the full Interim/Quarterly Report (IR).
2021-10-25 Chinese
关于控股股东部分股份解除质押的公告
Share Issue/Capital Change Classification · 95% confidence The document is an announcement regarding the release of pledged shares by the controlling shareholder of the company. It details the number of shares released from pledge, the shareholder's total pledged shares, and confirms no impact on company control or operations. There are no financial statements, earnings data, or management discussion. The document is a regulatory announcement about share pledge status, which fits the category of Share Issue/Capital Change (SHA) as it relates to changes in share capital status (pledge release). The document length is short and focused on share pledge information, not a full financial report or other categories.
2021-10-25 Chinese
关于计提资产减值准备的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Shenzhen Xintai Pharmaceutical Co., Ltd. regarding the provision for asset impairment. It details the decision made by the board of directors on October 22, 2021, to recognize asset impairment losses for inventory and fixed assets for the period ending September 30, 2021. The document includes the amount of impairment, the accounting standards applied, and the impact on the company's financials. It is a formal disclosure about a specific accounting adjustment rather than a full financial report or earnings release. The document is relatively short (2066 characters) and structured as an official announcement. It does not contain comprehensive financial statements or detailed financial analysis typical of an Interim/Quarterly Report (IR) or Annual Report (10-K). It also does not fit categories like Earnings Release (ER) or Management Reports (MDA) because it focuses solely on the impairment provision decision. Therefore, the best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other specific categories.
2021-10-25 Chinese
第五届监事会第十七次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Shenzhen Salubris Pharmaceuticals Co., Ltd. regarding the approval of the company's 2021 third quarter report and an asset impairment provision. It states that the third quarter report was reviewed and approved, but the actual report is referenced as being available elsewhere (on cninfo.com.cn and newspapers). The document itself is short (919 characters) and serves as an announcement of the meeting's resolutions rather than containing the full quarterly report or detailed financial data. Therefore, it is not the interim/quarterly report itself but an announcement related to it. This fits best with the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2021-10-25 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.